Your browser is no longer supported. Please, upgrade your browser.
Settings
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.21 Insider Own0.70% Shs Outstand148.07M Perf Week-5.76%
Market Cap9.38B Forward P/E833.29 EPS next Y0.08 Insider Trans-44.96% Shs Float147.10M Perf Month-11.09%
Income-30.10M PEG- EPS next Q-0.03 Inst Own97.00% Short Float3.74% Perf Quarter12.77%
Sales618.80M P/S15.15 EPS this Y-275.00% Inst Trans0.91% Short Ratio3.55 Perf Half Y47.93%
Book/sh9.51 P/B6.66 EPS next Y124.20% ROA-1.60% Target Price70.64 Perf Year46.63%
Cash/sh4.26 P/C14.86 EPS next 5Y7.10% ROE-2.20% 52W Range38.49 - 75.17 Perf YTD8.15%
Dividend- P/FCF- EPS past 5Y12.90% ROI-5.90% 52W High-15.75% Beta1.04
Dividend %- Quick Ratio6.30 Sales past 5Y28.30% Gross Margin71.60% 52W Low64.54% ATR2.55
Employees1300 Current Ratio6.70 Sales Q/Q13.40% Oper. Margin-14.10% RSI (14)35.23 Volatility4.20% 3.61%
OptionableYes Debt/Eq0.26 EPS Q/Q61.50% Profit Margin-4.90% Rel Volume0.93 Prev Close62.94
ShortableYes LT Debt/Eq0.25 EarningsApr 30 BMO Payout- Avg Volume1.55M Price63.33
Recom2.30 SMA20-6.38% SMA50-8.73% SMA20017.34% Volume1,436,594 Change0.62%
Jan-08-15Reiterated Mizuho Buy $72 → $81
Jul-31-14Reiterated Mizuho Buy $61 → $59
Apr-10-14Upgrade Mizuho Neutral → Buy $55 → $61
Apr-09-14Reiterated MKM Partners Sell $32 → $35
Feb-28-14Reiterated UBS Neutral $42 → $53
Feb-28-14Reiterated MKM Partners Sell $26 → $32
Feb-28-14Reiterated Mizuho Neutral $33 → $56
Dec-05-13Downgrade UBS Buy → Neutral $37 → $42
Nov-01-13Reiterated Mizuho Neutral $30 → $33
Oct-30-13Initiated FBR Capital Mkt Perform $31
May-24-13Reiterated UBS Buy $32 → $37
May-24-13Downgrade MKM Partners Neutral → Sell
Apr-18-13Downgrade Mizuho Buy → Neutral $30 → $26
Apr-17-13Reiterated MKM Partners Neutral $23 → $25
Jan-23-13Downgrade MKM Partners Buy → Neutral
Nov-16-12Initiated Mizuho Buy $27
Jan-25-12Upgrade MKM Partners Neutral → Buy $19 → $20
Aug-23-11Upgrade UBS Neutral → Buy $20.50 → $21
Jul-08-11Reiterated UBS Neutral $19 → $20.50
Jun-07-11Reiterated UBS Neutral $16.50 → $19
Mar-27-15 12:14PM  Alkermes 'Taking A Pause,' Citi Says
Mar-23-15 05:47PM  Alkermes plc -- Moody's affirms Alkermes' Ba3 ratings; changes outlook to stable at Moody's
07:04AM  Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on Schizophrenia Research at noodls
07:00AM  Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on Schizophrenia Research Business Wire
Mar-10-15 04:10PM  Alkermes Streamlines Operations, Revises 2015 Guidance - Analyst Blog
Mar-09-15 06:40AM  Alkermes to Sell Plant to Recro Pharma at The Wall Street Journal
06:10AM  Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro Pharma, Inc. at noodls
06:07AM  ALKERMES PLC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Office
06:00AM  Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro Pharma, Inc. Business Wire
Mar-04-15 06:25PM  Cramer: Best of biotech
Mar-03-15 05:00PM  Alkermes Intends to Add New Candidate to its Pipeline - Analyst Blog
04:00PM  Alkermes Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Business Wire
01:04PM  ALKERMES PLC. Financials EDGAR Online Financials
Mar-02-15 07:00AM  Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimers Agitation, Depression and Other CNS Diseases Business Wire
Feb-26-15 11:07AM  Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog Zacks
Feb-25-15 09:32AM  Alkermes Falls on Pipeline News; Q4 Earnings Plunge Y/Y - Analyst Blog Zacks
Feb-24-15 04:00PM  Alkermes Corporate Presentation to be Webcast at the Cowen and Company 35th Annual Health Care Conference Business Wire
12:55PM  Alkermes shares down after it stops development of pain pill at bizjournals.com
11:58AM  Alkermes beats Street 4Q forecasts AP
11:18AM  Jim Cramer: Use Share Weakness to Buy Alkermes for Its Drug Pipeline at TheStreet
10:21AM  Waiting for Yellen Q&A, but QE helping elsewhere at CNBC
08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today CCBN
07:54AM  Alkermes To Discontinue Development of Pain Treatment at The Wall Street Journal
07:07AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:07AM  Q4 2014 Alkermes Plc Earnings Release - Before Market Open CCBN
07:01AM  Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2014 and Provides Financial Expectations for 2015 Business Wire
07:00AM  Alkermes Announces Results From Phase 1 Study of ALKS 7106 Business Wire
Feb-23-15 04:00PM  Alkermes Announces Webcast of Analyst and Investor Event on March 2, 2015 Business Wire
07:00AM  Alkermes Appoints Mark Namchuk, Ph.D., As Senior Vice President of Research, Pharmaceutical and Nonclinical Development Business Wire
Feb-17-15 04:00PM  Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2014 Financial Results Business Wire
Feb-12-15 09:30AM  The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead, AbbVie, Regeneron and Alkermes - Press Releases Zacks
Feb-11-15 06:00AM  Jim Cramer's Top Stock Picks: GM HAS SAVE ALKS at TheStreet
Feb-10-15 08:35PM  Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News at TheStreet
04:20PM  Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog Zacks
Feb-09-15 07:14AM  Bull targeting Alkermes on pullback optionMONSTER
07:00AM  Alkermes Announces Positive Topline Results From Phase 1 Study of ALKS 8700 for Treatment of Multiple Sclerosis Business Wire
Feb-03-15 04:00PM  Alkermes Corporate Presentation to be Webcast at Two Upcoming Conferences Business Wire
Jan-27-15 06:00PM  Cramer: Wouldn't you rather own a winner than a whiner? CNBC
Jan-19-15 09:32AM  Alkermes plc (ALKS) in Focus: Stock Moves 6.6% Higher - Tale of the Tape Zacks
Jan-14-15 02:37PM  Why Citigroup Placed An $85 Price Target On Shares Of Alkermes Benzinga
Jan-07-15 02:47PM  Schizophrenia breakthrough? CNBC +9.55%
02:19PM  Alkermes stock surges after schizophrenia drug shows effectiveness without weight gain at American City Business Journals
02:10PM  Alkermes schizophrenia drug effective without the weight gain, early data show at bizjournals.com
01:00PM  Midday movers: Alkermes, Lennar, Radian Group & more at CNBC
12:55PM  Jim Cramer Says Alkermes Shares Are Going 'Much Higher' at TheStreet
12:03PM  Alkermes Hits High On Schizophrenia Drug Results at Investor's Business Daily
10:49AM  Alkermes CEO: Our Proprietary Drug Pipeline is 'Maturing Beautifully' at TheStreet
09:55AM  Cramer's Stop Trading: 'Holy Grail' drug CNBC
09:16AM  [$$] Alkermes Schizophrenia Drug Shows Less Weight Gain at The Wall Street Journal
09:06AM  SuperValu, J.C. Penney, Monsanto climb; Micron falls at MarketWatch
08:35AM  Alkermes shares up 5% on news of positive trial for schizophrenia drug at MarketWatch
08:24AM  Alkermes schizophrenia drug meets main goal in mid-stage trial Reuters
07:00AM  Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia Business Wire
Jan-06-15 04:00PM  Alkermes Corporate Presentation to be Webcast at the 33rd Annual J.P. Morgan Healthcare Conference Business Wire
12:55PM  Midday movers: Chevron, Hess, Morgan Stanley & more at CNBC
09:55AM  Cramer's Stop Trading: Biotech underestimated CNBC
07:00AM  Alkermes Announces Positive Results From Study of ALKS 5461 for Treatment of Major Depressive Disorder Business Wire
Dec-15-14 07:00AM  Alkermes Announces Initiation of Clinical Study of Extended Durations of Aripiprazole Lauroxil for Treatment of Schizophrenia Business Wire
Dec-05-14 04:53PM  ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
Nov-25-14 04:02PM  Alkermes Corporate Presentation to be Webcast at The NASDAQ OMX 31st Investor Program Business Wire
Nov-18-14 06:00PM  Cramer shares hazards of skepticism CNBC
Nov-13-14 11:30AM  ALKERMES PLC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Nov-04-14 04:00PM  Alkermes Corporate Presentation to be Webcast at the Credit Suisse 2014 Healthcare Conference Business Wire
Oct-31-14 03:30PM  Alkermes Incurs Wider Q3 Loss but Revenues Grow Y/Y Zacks
Oct-29-14 10:07AM  Alkermes reports 3Q loss AP
08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today CCBN
07:11AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:07AM  Q3 2014 Alkermes Plc Earnings Release - Before Market Open CCBN
07:00AM  Alkermes plc Reports Third Quarter 2014 Financial Results Business Wire
Oct-22-14 04:00PM  Alkermes to Host Conference Call to Discuss Third Quarter 2014 Financial Results Business Wire
07:00AM  Alkermes New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA Business Wire
Sep-24-14 06:15PM  Cramer's favorite large cap biotech plays CNBC
09:45AM  ALKERMES PLC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Sep-16-14 06:00AM  'Mad Money' Lightning Round: Buy, Buy, Buy St Jude Medical at TheStreet
Sep-04-14 05:10PM  Alkermes Completes Enrolment for Phase II ALKS 3831 Study Zacks
Sep-03-14 05:14PM  Massachusetts jail offers $1,000-a-shot drug to fight addiction, recidivism Reuters
10:45AM  Credit Suisses 4 Top Pharmaceutical Stocks to Buy for the Rest of 2014 24/7 Wall St.
07:00AM  Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic Business Wire
Sep-02-14 04:00PM  Alkermes Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Business Wire
Aug-27-14 06:10PM  Alkermes Begins a Study on ALKS7106 for Treatment of Pain Zacks
Aug-26-14 06:00PM  Alkermes Gains on Aripiprazole Lauroxil NDA Submission Zacks
07:00AM  Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 7106 for Treatment of Pain Business Wire
Aug-25-14 07:00AM  Alkermes Submits New Drug Application to FDA for Aripiprazole Lauroxil for Treatment of Schizophrenia Business Wire
Aug-08-14 10:25AM  Wall Street Transcript Interview with Howard Zauberman, the President and CEO of Vision-Sciences, Inc. (VSCI) Wall Street Transcript
Aug-04-14 02:40PM  Alkermes Reports Loss in Q2 on Higher Costs, Revenues Up Zacks
Jul-31-14 08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today CCBN -7.69%
07:07AM  Q2 2014 Alkermes plc Earnings Release - Before Market Open CCBN
07:05AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:00AM  Alkermes plc Reports Second Quarter 2014 Financial Results Business Wire
Jul-30-14 07:00AM  Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major Depressive Disorder Business Wire
Jul-24-14 04:00PM  Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results Business Wire
Jul-23-14 07:10AM  Is Alkermes plc Stock Undervalued? at Motley Fool
Jul-21-14 03:40PM  Alkermes' Pipeline Development Impresses, Key Updates Ahead Zacks
Jul-17-14 07:05AM  Alkermes announces initiation of Phase 1 study of ALKS 8700 for treatment of MS at theflyonthewall.com
07:00AM  Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis Business Wire
Jul-09-14 07:00AM  Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates Business Wire
Jul-08-14 12:47PM  Momentum names slammed as volatility comes back at CNBC
09:55AM  Why Mylan Should Buy Alkermes at Motley Fool
Jun-23-14 07:04AM  Alkermes plc (ALKS) Jumps: Stock Rises 5.7% Zacks
Jun-20-14 07:00AM  Lundbeck Delivers Some Data-Driven Upside at Seeking Alpha +5.71%
Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. The company offers RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia schizoaffective disorder; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; and VIVITROL for alcohol and opioid dependence. It is also developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a Phase II study medicine to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is under Phase I study to treat multiple sclerosis; ALKS 7106, a drug candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary investigational biologic cancer immunotherapy product that is under pre-clinical stage. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. Alkermes Public Limited Company was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cooke ShanePresident, Alkermes plcMar 23Option Exercise14.6018,000262,80053,180Mar 24 05:15 PM
Cooke ShanePresident, Alkermes plcMar 23Sale65.3318,0001,175,92535,180Mar 24 05:15 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Mar 16Option Exercise18.1118,000325,89042,956Mar 17 05:01 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Mar 16Sale66.8118,0001,202,50424,956Mar 17 05:01 PM
FRATES JAMES MSVP & CFO, Alkermes plcMar 10Option Exercise9.2110,00092,10088,649Mar 11 05:53 PM
FRATES JAMES MSVP & CFO, Alkermes plcMar 10Sale66.2510,000662,49678,649Mar 11 05:53 PM
Peterson RebeccaSVP, Corporate CommunicationsMar 05Sale71.802,362169,5960Mar 05 05:29 PM
Stejbach MarkChief Commercial OfficerMar 03Option Exercise0.002,812011,678Mar 05 06:19 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Mar 03Option Exercise0.003,25009,889Mar 05 06:10 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 03Option Exercise0.0013,0000533,063Mar 05 06:07 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 03Option Exercise0.002,8120133,333Mar 05 05:59 PM
FRATES JAMES MSVP & CFO, Alkermes plcMar 03Option Exercise0.002,812079,974Mar 05 05:53 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Mar 03Option Exercise0.003,750026,723Mar 05 05:48 PM
Cooke ShanePresident, Alkermes plcMar 03Option Exercise0.005,250037,910Mar 05 05:42 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Mar 03Option Exercise0.003,500083,162Mar 05 05:37 PM
Peterson RebeccaSVP, Corporate CommunicationsMar 03Option Exercise38.4218,875725,08515,375Mar 05 05:29 PM
Peterson RebeccaSVP, Corporate CommunicationsMar 03Sale71.3115,3751,096,3720Mar 05 05:29 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Mar 02Option Exercise18.1115,000271,57521,639Mar 03 05:51 PM
BREYER ROBERT ADirectorMar 02Option Exercise14.925,00074,60058,156Mar 03 05:34 PM
BREYER ROBERT ADirectorMar 02Sale70.865,000354,30053,156Mar 03 05:34 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Mar 02Sale71.3915,0001,070,9056,639Mar 03 05:51 PM
Cooke ShanePresident, Alkermes plcFeb 23Option Exercise14.6018,000262,80050,660Feb 23 05:54 PM
Cooke ShanePresident, Alkermes plcFeb 23Sale74.2918,0001,337,30432,660Feb 23 05:54 PM
Ehrich ElliotSVP, R&D & CMO, Alkermes, Inc.Feb 17Option Exercise18.1118,000325,89040,973Feb 18 05:19 PM
Ehrich ElliotSVP, R&D & CMO, Alkermes, Inc.Feb 17Sale70.8718,0001,275,69122,973Feb 18 05:19 PM
FRATES JAMES MSVP & CFO, Alkermes plcFeb 03Option Exercise9.2110,00092,10087,162Feb 04 05:53 PM
FRATES JAMES MSVP & CFO, Alkermes plcFeb 03Sale70.8310,000708,30677,162Feb 04 05:53 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Feb 02Option Exercise18.1115,000271,57521,639Feb 04 05:49 PM
BREYER ROBERT ADirectorFeb 02Option Exercise14.925,00074,60058,156Feb 04 05:51 PM
BREYER ROBERT ADirectorFeb 02Sale72.915,000364,55053,156Feb 04 05:51 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Feb 02Sale72.0115,0001,080,1096,639Feb 04 05:49 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Jan 26Option Exercise18.1115,000271,57521,639Jan 27 06:28 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Jan 26Sale70.0215,0001,050,2876,639Jan 27 06:28 PM
Cooke ShanePresident, Alkermes plcJan 23Option Exercise14.60118,0001,722,800150,660Jan 26 06:14 PM
Cooke ShanePresident, Alkermes plcJan 23Sale69.13118,0008,157,23432,660Jan 26 06:14 PM
BLOOM FLOYD EDirectorJan 16Sale67.0716,5001,106,58290,281Jan 20 06:28 PM
Ehrich ElliotSVP, R&D & CMO, Alkermes, Inc.Jan 15Option Exercise18.1218,375332,86541,348Jan 16 05:49 PM
Ehrich ElliotSVP, R&D & CMO, Alkermes, Inc.Jan 15Sale66.4518,3751,221,07122,973Jan 16 05:49 PM
BLOOM FLOYD EDirectorJan 15Sale67.363,500235,750106,781Jan 20 06:28 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Jan 07Option Exercise18.6028,374527,756108,036Jan 08 06:18 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Jan 07Sale65.0028,3741,844,31079,662Jan 08 06:18 PM
BREYER ROBERT ADirectorJan 02Option Exercise14.925,00074,60058,156Jan 05 05:32 PM
BREYER ROBERT ADirectorJan 02Sale58.575,000292,85053,156Jan 05 05:32 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 11Option Exercise14.9050,000745,000570,063Dec 11 06:01 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 11Sale56.2050,0002,810,050520,063Dec 11 06:01 PM
FRATES JAMES MSVP & CFO, Alkermes plcDec 10Option Exercise11.8818,870224,26396,032Dec 11 05:49 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 10Option Exercise14.9050,000745,000570,063Dec 11 06:01 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 10Sale55.8850,0002,794,139520,063Dec 11 06:01 PM
FRATES JAMES MSVP & CFO, Alkermes plcDec 10Sale56.0718,8701,057,98477,162Dec 11 05:49 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Dec 09Option Exercise14.9018,000268,200148,521Dec 11 05:41 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Dec 09Sale56.8218,0001,022,809130,521Dec 11 05:41 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Dec 05Option Exercise14.9015,433229,95295,095Dec 05 05:41 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Dec 05Sale57.6115,433889,05679,662Dec 05 05:41 PM
FRATES JAMES MSVP & CFO, Alkermes plcDec 03Option Exercise14.908,000119,20085,162Dec 05 05:38 PM
FRATES JAMES MSVP & CFO, Alkermes plcDec 03Sale55.728,000445,77877,162Dec 05 05:38 PM
BREYER ROBERT ADirectorDec 01Option Exercise18.295,00091,45058,156Dec 02 05:40 PM
BREYER ROBERT ADirectorDec 01Sale54.645,000273,20053,156Dec 02 05:40 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Nov 26Option Exercise8.5511,696100,00181,479Nov 26 05:20 PM
FRATES JAMES MSVP & CFO, Alkermes plcNov 19Option Exercise14.908,000119,20085,162Nov 21 05:09 PM
FRATES JAMES MSVP & CFO, Alkermes plcNov 19Sale53.868,000430,89877,162Nov 21 05:09 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Nov 13Option Exercise11.748,51799,99041,044Nov 13 05:12 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 13Option Exercise14.9050,000745,000570,063Nov 13 05:11 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 13Sale52.8850,0002,643,990520,063Nov 13 05:11 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 12Option Exercise14.9050,000745,000570,063Nov 13 05:11 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 12Sale52.8650,0002,643,175520,063Nov 13 05:11 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 11Option Exercise14.9015,000223,500145,521Nov 13 05:08 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Nov 11Option Exercise14.9015,000223,50084,783Nov 13 05:09 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Nov 11Sale52.7415,000791,07569,783Nov 13 05:09 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 11Sale52.7415,000791,121130,521Nov 13 05:08 PM
FRATES JAMES MSVP & CFO, Alkermes plcNov 07Option Exercise12.3713,303164,54190,465Nov 07 05:46 PM
FRATES JAMES MSVP & CFO, Alkermes plcNov 07Sale49.9813,303664,94477,162Nov 07 05:46 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Nov 06Option Exercise14.9020,000298,00089,783Nov 07 05:42 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Nov 06Sale50.5420,0001,010,72869,783Nov 07 05:42 PM
BREYER ROBERT ADirectorNov 03Option Exercise18.295,00091,45058,156Nov 04 06:02 PM
BREYER ROBERT ADirectorNov 03Sale50.055,000250,25053,156Nov 04 06:02 PM
FRATES JAMES MSVP & CFO, Alkermes plcOct 31Option Exercise13.3944,805599,97479,140Nov 04 05:59 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Oct 23Option Exercise16.5514,577241,24947,104Oct 23 05:17 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Oct 23Sale45.0014,577655,96532,527Oct 23 05:17 PM
POPS RICHARD FDirector and CEO, Alkermes plcOct 16Option Exercise14.9050,000745,000570,063Oct 16 05:30 PM
POPS RICHARD FDirector and CEO, Alkermes plcOct 16Sale41.1850,0002,058,912520,063Oct 16 05:30 PM
POPS RICHARD FDirector and CEO, Alkermes plcOct 15Option Exercise14.9050,000745,000570,063Oct 16 05:30 PM
POPS RICHARD FDirector and CEO, Alkermes plcOct 15Sale41.0650,0002,053,110520,063Oct 16 05:30 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Oct 14Option Exercise14.9015,000223,500145,521Oct 16 05:26 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Oct 14Sale40.6515,000609,737130,521Oct 16 05:26 PM
FRATES JAMES MSVP & CFO, Alkermes plcOct 08Option Exercise11.7316,000187,60060,225Oct 10 05:20 PM
FRATES JAMES MSVP & CFO, Alkermes plcOct 08Sale41.0016,000656,07744,225Oct 10 05:20 PM
Cooke ShanePresident, Alkermes plcOct 05Option Exercise0.0012,500039,160Oct 06 05:35 PM
BREYER ROBERT ADirectorOct 01Option Exercise18.295,00091,45058,156Oct 03 05:06 PM
BREYER ROBERT ADirectorOct 01Sale42.595,000212,95053,156Oct 03 05:06 PM
FRATES JAMES MSVP & CFO, Alkermes plcSep 24Option Exercise11.7316,000187,60060,225Sep 24 05:25 PM
FRATES JAMES MSVP & CFO, Alkermes plcSep 24Sale45.2916,000724,64044,225Sep 24 05:25 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Sep 18Option Exercise14.9015,000223,500145,521Sep 19 05:23 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Sep 18Sale45.6015,000684,063130,521Sep 19 05:23 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 17Option Exercise14.9050,000745,000570,063Sep 19 05:19 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Sep 17Option Exercise15.9114,900237,08647,427Sep 19 05:21 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Sep 17Sale45.0414,900671,04732,527Sep 19 05:21 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 17Sale44.8950,0002,244,585520,063Sep 19 05:19 PM
FRATES JAMES MSVP & CFO, Alkermes plcSep 10Option Exercise11.7316,000187,60060,225Sep 12 05:05 PM
FRATES JAMES MSVP & CFO, Alkermes plcSep 10Sale43.1816,000690,82644,225Sep 12 05:05 PM
MITCHELL PAUL JDirectorSep 02Option Exercise11.841,00011,8409,000Sep 02 05:07 PM